Welcome to the new version of CaltechAUTHORS. Login is currently restricted to library staff. If you notice any issues, please email coda@library.caltech.edu
Published April 13, 2023 | public
Journal Article

Discovery and Binding Mechanism of Pyrazoloisoquinoline-Based Novel β-Arrestin Inverse Agonists of the Kappa-Opioid Receptor

Abstract

Chronic exposure to stress or unwanted stimuli has been known to activate kappa opioid receptor/dynorphin (KOR/DYN) systems, which could induce depressive states and develop into some psychiatric disorders. Here, we report the first discovery of pyrazoloisoquinoline-based novel KOR β-arrestin inverse agonists through synthesis, structure–activity relationships, optimization, and the biological evaluations of μ/κ/δ opioid receptor activities with cAMP and β-arrestin recruitment assays. The optimized compound 7q shows potent and selective β-arrestin inverse agonism at KOR with an EC₅₀ value of 9.33 nM in contrast to lower activities at DOR and no activity at MOR. Moreover, we use molecular dynamics simulations to predict the binding mode of the inverse agonist and propose a mechanism for the inverse agonism. We find that the transmembrane helix 6 position of the activated state is different for the OR subtypes, leading to significantly different interactions between the receptor and β-arrestin.

Additional Information

© 2023 American Chemical Society. This work was supported by the GIST-Caltech Research Collaboration grant funded by the GIST in 2016-2019 and "GIST Research Institute(GRI) IIBR" grant funded by the GIST in 2022. The Caltech team was supported by NIH (R01HL155532). Author Contributions. J.-H.J., I.H.J., and M.Y.Y. contributed equally to this work as first co-authors. The authors declare no competing financial interest.

Additional details

Created:
August 22, 2023
Modified:
October 18, 2023